April 18 is European Patients’ Rights Day (EPRD).
More specifically, this charter proclaims:
The European Clinical Trials Regulation (Regulation (EU) No 536/2014) also aims to guarantee the rights of patients, and all of the medical writers at Synergy Pharm/Santé Active Edition are committed to ensuring that information relating to compliance with ethical standards and good clinical practice is clearly stated in publications reporting the results of clinical trials.
On the occasion of the national “Week Against Cancer” campaign in France, it is important to highlight research efforts aimed at reducing the side effects associated with cancer treatments.
Indeed, while the range of treatments available – used alone or in combination – are effective against cancer, they can have many side effects, particularly on the skin. Xerosis is one of the most frequent side effects of cancer therapy and requires appropriate management to help maintain patient quality of life and prevent potential interruptions to cancer treatment.
A recent multicenter, real-world, phase IV study demonstrated the benefits of using an emollient containing a postbiotic in the management of 319 patients with xerosis associated with a range of cancer treatments (chemotherapy, targeted therapy, radiotherapy, hormonotherapy and immunotherapy).
A previous multicentre, real-world, phase IV study had already demonstrated the effectiveness of this emollient for the management of xerosis in 5,910 patients with a range of skin conditions (atopic dermatitis, senile xerosis, ichthyosis, psoriasis, prurigo nodularis of Hyde etc.) and underlying systemic conditions (diabetes mellitus, thyroid disease, renal insufficiency, etc.).
These two articles, published in Dermatology and Therapy and written by our medical writing team, can be found here:
*Learning, Brain and Artificial Intelligence, Brain and New Technologies, Brain and Society, Brain and Sport, Sleep, The 5 senses, Emotions, Memory, The Sick Brain.
By definition, a rare disease has a prevalence of 1/2,000. But rare diseases are numerous and would affect more than 3 million people in France, more than 300 million in the world!
Most of these diseases have no treatment. Nevertheless, many actors are mobilized in the fight against rare diseases to improve the diagnosis, care and follow-up of the patients concerned; research in this area also allows significant medical advances.
In 2021, we again had the opportunity to put our medical writing skills at the service of several rare diseases, including craniofacial microsomia, cystic fibrosis, and inherited epidermolysis bullosa.Read more
On Sunday 30 January 2022, the WHO will celebrate the World Neglected Tropical Diseases Day (WNTDD). The WHO activities aim to mobilize the world to defeat NTD (https://www.who.int/campaigns/world-ntd-day/world-ntd-day-2022).Read more
Although hair disorders are common, their management still represents a major clinical challenge in dermatological practice despite the emergence of new diagnostic tools and new treatment options.Read more
Today is World Psoriasis Day. It is a great opportunity to share a review of the literature on this chronic skin pathology.Read more
October is Breast Cancer Screening Awareness Month.
More than 355,000 women were newly diagnosed with breast cancer, and nearly 92,000 women died from the disease across the EU-27 in 2020.Read more